Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Hanna Sanoff, MD
UNC Lineberger Comprehensive Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ireland Cooperative Clinical Research Group
Dublin, Ireland
- Rocky Mountain Cancer Centers
Denver, Colorado, United States
- Mount Sinai Medical Center-Miami
Miami, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Emory University
Atlanta, Georgia, United States
- Georgia Cancer Specialists
Atlanta, Georgia, United States
- Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
- University of Louisville James Brown Cancer Center
Louisville, Kentucky, United States
- North Shore Long Island Jewish Health System
Manhasset, New York, United States
- New York University Langone Medical Center
New York, New York, United States
- Seby B. Jones Cancer Center
Boone, North Carolina, United States
- University of North Carolina
Chapel Hill, North Carolina, United States
- Carolinas Healthcare System
Charlotte, North Carolina, United States
- Southeast Medical Oncology Center
Goldsboro, North Carolina, United States
- the Moses Cone Regional Cancer Center
Greensboro, North Carolina, United States
- Leo W. Jenkins Cancer Center at Ecu Medical School
Greenville, North Carolina, United States
- First Health of the Carolinas, Moore Regional Hospital
Pinehurst, North Carolina, United States
- Rex Cancer Center at Rex Hospital
Raleigh, North Carolina, United States
- Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
- University of Cincinnati
Cincinnati, Ohio, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Virginia
Charlottesville, Virginia, United States
- Portsmouth Naval Medical Center
Portsmouth, Virginia, United States
- Multicare Regional Cancer Center
Tacoma, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Apr 2011
- Primary completion
- 15 Nov 2016
- Completion
- 2 Oct 2020
- Last update posted
- 6 Jan 2021
- Registered enrollment
- 181
- Registry id
- NCT01298570
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.